Clostridium novyi alpha toxin (TcnA)

Clostridium novyi alpha toxin (TcnA) is a potent protein exotoxin and the primary virulence factor produced by the anaerobic bacterium Clostridium novyi, which is the causative agent of gas gangrene and infectious myonecrosis (UniProt P0C216). As a member of the Large Clostridial Toxin (LCT) family, it shares structural homology with toxins from Clostridium difficile and acts as a glucosyltransferase that targets host Rho-family GTPases such as Rho, Rac, and Cdc42 (PMID: 10490043). By covalently modifying these molecular switches, the toxin disrupts the actin cytoskeleton and vital intracellular signaling pathways, ultimately leading to cell death and extensive tissue damage. In modern biotechnology, the toxin is a focal point of oncology research; while the wild-type toxin is highly lethal, an attenuated strain of the bacteria known as C. novyi-NT (Non-Toxic) has had the alpha toxin gene deleted to serve as a safe, tumor-targeting agent that thrives in the hypoxic regions of solid cancers (PMID: 25122631). Understanding the toxin's mechanism is critical for both developing antitoxins against clostridial infections and refining bacterial-mediated tumor therapies.

Other names

Alpha-toxinTcnAUDP-glucose:Rho GTPase glucosyltransferaseClostridium novyi type A alpha toxin

The toxin functions as a glucosyltransferase that enters host cells via receptor-mediated endocytosis and translocates its catalytic domain into the cytosol. It catalyzes the covalent transfer of a glucose moiety from UDP-glucose to a conserved threonine residue (Thr-37 in Rho; Thr-35 in Rac/Cdc42) of Rho-family GTPases (PMID: 10490043). This modification prevents the GTPases from interacting with their downstream effectors, leading to the collapse of the actin cytoskeleton, cell rounding, and eventual cell death (PMID: 15530383).